HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Consumer Health Sector Holds Private Equity Investors' Attention

This article was originally published in The Rose Sheet

You may also be interested in...



Nestle Acquires IM HealthScience, Expands Medical Food Lineup In Latest US Consumer Move

Nestle Health Science acquires IM HealthScience, marketer of medical foods IBgard and FDgard as well as prebiotic and sleep aid supplements. The deal is second recent US consumer health addition for the firm after it said 2020 would be “‘more vigorous” year for acquisitions despite the COVID-19 pandemic.

Growth Approaches: Entrepreneur P&G, Top Brand Church & Dwight, Practice Patience Clorox

P&G, Church & Dwight and Clorox executives say firms are looking to add brands to portfolios. P&G's developing assets through a brand creation project; C&D seeks top brands, largely in non-US markets; and Clorox looks for opportunities in select ‘spaces’ in US health, wellness and personal care.

Glaxo Opts For Solo Navigation To Boost Control In Consumer Health Market

After announcing the $13bn acquisition of Novartis' 36.5% share of their JV, GSK said its Horlicks nutritional beverage line and its consumer health subsidiary in India, the source of most Horlicks sales, are potential divestments. The firm also will consider selling other consumer health nutrition products.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS121537

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel